1. Home
  2. PRSO vs BCAB Comparison

PRSO vs BCAB Comparison

Compare PRSO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$1.39

Market Cap

7.8M

Sector

Technology

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$4.51

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
BCAB
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
7.5M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
PRSO
BCAB
Price
$1.39
$4.51
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$3.00
N/A
AVG Volume (30 Days)
716.4K
32.3K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
29.86
EPS
N/A
N/A
Revenue
$14,573,000.00
$300,000.00
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.77
$0.12
52 Week High
$2.37
$6.52

Technical Indicators

Market Signals
Indicator
PRSO
BCAB
Relative Strength Index (RSI) 71.22 56.41
Support Level $1.38 $0.36
Resistance Level $1.63 $6.33
Average True Range (ATR) 0.08 0.50
MACD 0.03 -0.17
Stochastic Oscillator 69.63 28.50

Price Performance

Historical Comparison
PRSO
BCAB

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: